Global Spinal Muscular Atrophy (SMA) Clinical Trials Review H1, 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Spinal Muscular Atrophy (SMA) Clinical Trials Review H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

This clinical trial report, Global Spinal Muscular Atrophy (SMA) Clinical Trials Review H1, 2020 provides an overview of Spinal Muscular Atrophy (SMA) Clinical trials scenario.

The report provides top line data relating to the clinical trials on Spinal Muscular Atrophy (SMA). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered

1. Report Guidance
2. Clinical Trials Report Coverage
3. Clinical Trials by Region
4. Clinical Trials and Average Enrollment by Country
5. Top Five Countries Contributing to Clinical Trials in Asia-Pacific
6. Top Five Countries Contributing to Clinical Trials in Europe
7. Top Countries Contributing to Clinical Trials in North America
8. Top Countries Contributing to Clinical Trials in Middle East and Africa
9. Top Countries Contributing to Clinical Trials in Central and South America
10. Clinical Trials by G7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials
11. Clinical Trials by Phase in G7 Countries
12. Clinical Trials in G7 Countries by Trial Status
13. Clinical Trials by E7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials
14. Clinical Trials by Phase in E7 Countries
15. Clinical Trials in E7 Countries by Trial Status
16. Clinical Trials by Phase
17. In Progress Trials by Phase
18. Clinical Trials by Trial Status
19. Clinical Trials by End Point Status
20. Subjects Recruited Over a Period of Time
21. Clinical Trials by Sponsor Type
22. Prominent Sponsors
23. Top Companies Participating in Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials
24. Prominent Drugs
25. Latest Clinical Trials News on Spinal Muscular Atrophy (SMA)
26. Nov 25, 2019: Genentech gets FDA priority review status for risdiplam in SMA
27. Nov 19, 2019: Scholar Rock reports preliminary pharmacokinetic and pharmacodynamic data from TOPAZ phase 2 trial of SRK-015 for the treatment of patients with spinal muscular atrophy
28. Nov 12, 2019: Roche and PTC report positive data for risdiplam in SMA
29. Clinical Trial Profile Snapshots

Companies Mentioned

• F. Hoffmann-La Roche Ltd.
• Biogen Inc.
• Novartis AG
• PTC Therapeutics Inc.
• Cytokinetics Inc.
• Ionis Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Cure SMA
• PRA Health Sciences Inc.
• Abbott Laboratories

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/rf52ak